Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISMIGEN in asthmatic children
NCT02541331Phase 3Completed
- Sponsor
- Lallemand Inc.
- Start
- Jul 2014
- Primary completion
- Jun 2015
- Modality
- Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic asthma comparing ISMIGEN with Placebo (2 arms). Primary endpoint: Asthma Control Test at 3 months. Started Jul 2014; status: completed.
02
Drugs
polyvalent mechanical bacterial lysate
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT02541331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02541331.